Increased SIRT6 expression has been reported in pancreatic, prostate and breast cancers, where high SIRT6 levels are associated with chemotherapy resistance and poor prognosis (Bauer et al., 2012; Khongkow et al., 2013; Liu et al., 2013b). Here, SIRT6 is linked to breast cancer.